
Bladder cancer - Pipeline Insight, 2022
Description
Bladder cancer - Pipeline Insight, 2022
DelveInsight’s, “Bladder cancer - Pipeline Insight, 2022,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Bladder cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Bladder cancer: Overview
Bladder cancer is a disease that usually begins in the cells that line the inside of the bladder. It typically affects people older than 70 and occurs more often in men. Bladder cancer is the fifth most common form of cancer overall and the fourth most common among men. Bladder cancer usually responds well to treatment when diagnosed early. However, people who have been successfully treated for bladder cancer should be monitored afterward. Bladder cancer can return even years later. About 90 percent of bladder cancers begin in the cells on the surface of the bladder’s inner lining. This type of cancer is called urothelial carcinoma (also called transitional cell carcinoma). Most urothelial carcinoma is non-muscle invasive. That means the cancer stays within the bladder’s inner lining. Less common types of bladder cancer include squamous cell carcinoma, adenocarcinoma, and small cell carcinoma. These types can develop in the inner lining as a result of chronic irritation and inflammation. They usually grow into the muscle of the bladder over time. In most cases, the first sign of bladder cancer is blood in the urine. Other symptoms may include feeling pain or burning during urination or a change in urination habits. This can include frequent urination or a need to go but being unable to pass urine. More-advanced bladder cancer may involve lower back pain on one side, feeling tired or weak, or having no appetite and losing weight. Tobacco use is by far the biggest risk factor for developing bladder cancer. People who smoke cigarettes are up to four times more likely than nonsmokers to develop the disease. Studies have shown that smoking is responsible for approximately 50 percent of bladder cancers.
""Bladder cancer - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Bladder cancer pipeline landscape is provided which includes the disease overview and Bladder cancer treatment guidelines. The assessment part of the report embraces, in depth Bladder cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Bladder cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Bladder cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Bladder cancer Emerging Drugs
Further product details are provided in the report……..
Bladder cancer: Therapeutic Assessment
This segment of the report provides insights about the different Bladder cancer drugs segregated based on following parameters that define the scope of the report, such as:
Bladder cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Bladder cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bladder cancer drugs.
Bladder cancer Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Bladder cancer - Pipeline Insight, 2022,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Bladder cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Bladder cancer: Overview
Bladder cancer is a disease that usually begins in the cells that line the inside of the bladder. It typically affects people older than 70 and occurs more often in men. Bladder cancer is the fifth most common form of cancer overall and the fourth most common among men. Bladder cancer usually responds well to treatment when diagnosed early. However, people who have been successfully treated for bladder cancer should be monitored afterward. Bladder cancer can return even years later. About 90 percent of bladder cancers begin in the cells on the surface of the bladder’s inner lining. This type of cancer is called urothelial carcinoma (also called transitional cell carcinoma). Most urothelial carcinoma is non-muscle invasive. That means the cancer stays within the bladder’s inner lining. Less common types of bladder cancer include squamous cell carcinoma, adenocarcinoma, and small cell carcinoma. These types can develop in the inner lining as a result of chronic irritation and inflammation. They usually grow into the muscle of the bladder over time. In most cases, the first sign of bladder cancer is blood in the urine. Other symptoms may include feeling pain or burning during urination or a change in urination habits. This can include frequent urination or a need to go but being unable to pass urine. More-advanced bladder cancer may involve lower back pain on one side, feeling tired or weak, or having no appetite and losing weight. Tobacco use is by far the biggest risk factor for developing bladder cancer. People who smoke cigarettes are up to four times more likely than nonsmokers to develop the disease. Studies have shown that smoking is responsible for approximately 50 percent of bladder cancers.
""Bladder cancer - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Bladder cancer pipeline landscape is provided which includes the disease overview and Bladder cancer treatment guidelines. The assessment part of the report embraces, in depth Bladder cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Bladder cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Bladder cancer.
- In the coming years, the Bladder cancer market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics that are working to assess challenges and seek opportunities that could influence Bladder cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- A detailed portfolio of major pharma players who are involved in fueling the Bladder cancer treatment market. Several potential therapies for Bladder cancer are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Bladder cancer market size in the coming years.
- Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Bladder cancer) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
This segment of the Bladder cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Bladder cancer Emerging Drugs
- CG0070: CG Oncology
- N-803: ImmunityBio
- UGN-102: UroGen
- Trilaciclib: G1 Therapeutics
Further product details are provided in the report……..
Bladder cancer: Therapeutic Assessment
This segment of the report provides insights about the different Bladder cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Bladder cancer
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Inhalation
- Inhalation/Intravenous/Oral
- Intranasal
- Intravenous
- Intravenous/ Subcutaneous
- NA
- Oral
- Oral/intranasal/subcutaneous
- Parenteral
- Subcutaneous
- Molecule Type
- Antibody
- Antisense oligonucleotides
- Immunotherapy
- Monoclonal antibody
- Peptides
- Protein
- Recombinant protein
- Small molecule
- Stem Cell
- Vaccine
- Product Type
Bladder cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Bladder cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bladder cancer drugs.
Bladder cancer Report Insights
- Bladder cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Bladder cancer drugs?
- How many Bladder cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Bladder cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Bladder cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Bladder cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
- CG Oncology
- ImmunityBio
- UroGen
- G1 Therapeutics
- FKD Therapies
- Bristol-Myers Squibb
- LintonPharm Co.,Ltd.
- Nektar Therapeutics
- Hamlet Pharma AB
- Asieris Pharmaceuticals
- Wuhan Binhui Biotechnology
- Pfizer
- Taizhou Hanzhong biomedical co. LTD
- Hoffmann-La Roche
- Protara Therapeutics
- AstraZeneca
- CicloMed LLC
- enGene, Inc.
- Emtora Biosciences
- Qilu Pharmaceutical Co., Ltd.
- Theralase Inc.
- Vaxiion Therapeutics
- Janssen Research & Development, LLC
- Seagen Inc.
- RemeGen Co., Ltd.
- Taiho Oncology, Inc.
- Xennials Therapeutics
- Flame Biosciences
- Lindis Biotech
- Incyte Corporation
- Eli Lilly and Company
- Daiichi Sankyo
- Nektar Therapeutics
- Pieris Pharmaceuticals, Inc.
- Istari Oncology, Inc.
- BeiGene
- Vyriad, Inc.
- Adlai Nortye Biopharma Co., Ltd.
- Kyowa Kirin, Inc.
- Infinity Pharmaceuticals, Inc.
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- HiberCell, Inc.
- Ikena Oncology
- Fusion Pharmaceuticals Inc.
- GI Innovation, Inc.
- SOTIO a.s.
- Celon Pharma SA
- Shanghai PerHum Therapeutics Co., Ltd.
- 4D Pharma PLC
- CG0070
- N-803
- UGN-102
- CPL304110
- SO-C101
- Trilaciclib
- Tislelizumab
- MRx0518
- CCT301-59
- GI-101
- INSTILADRIN
- FPI-1966
- IK-175
- HC-7366
- Lerapolturev
- SHR-1501
- IPI-549
- KHK2455
- MV-NIS
- AN0025
- PRS-343
- AZD8853
- VAX014
- TLD-1433
- Bempegaldesleukin
- Trastuzumab deruxtecan
- Nivolumab
- Abemaciclib
- Catumaxomab
- Pemigatinib
- VB4-845
- FL-101
- Catumaxomab
- NTX-301
- TAS 102
- eRapa
- Bempegaldesleukin
- Enfortumab vedotin
- RC48-ADC
- EG-70
- CPX-POM
- alpha1H
- APL-1202
- Erdafitinib
- OH2
- PF-07225570
- HX008
- Atezolizumab
- TARA-002
- Durvalumab
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Table of Contents
280 Pages
- Introduction
- Executive Summary
- Bladder cancer: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Bladder cancer – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- CG0070: CG Oncology
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Trilaciclib: G1 Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- MV-NIS: Vyriad
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- FEP 633: PRISM BioLab
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Bladder cancer Key Companies
- Bladder cancer Key Products
- Bladder cancer- Unmet Needs
- Bladder cancer- Market Drivers and Barriers
- Bladder cancer- Future Perspectives and Conclusion
- Bladder cancer Analyst Views
- Bladder cancer Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.